title: Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme.
abstract: The putative role of the CAPL gene in enhancing the development of human cancer metastasis was examined by transfecting human high-expressing osteosarcoma cells with a hammerhead ribozyme directed against the gene transcript. The ability of the ribozyme to cleave target mRNA in intact cells was demonstrated in a 5'-rapid amplification of cDNA ends assay. In transfected cells, a suppression of the capacity to give skeletal metastases upon intracardial injection into nude rats was observed in cell clones with reduced expression of CAPL mRNA and protein, whereas in vitro and in vivo cell proliferation and tumorigenicity were unchanged. The results provide direct evidence that the expression level of the CAPL-encoded protein can determine the metastatic potential of osteosarcoma cells, and they demonstrate an association between reduced gene expression and proliferation-independent inhibition of the metastatic capacity of human tumor cells. The effects of the specific cleavage of CAPL mRNA indicate that the gene product is involved in key cellular functions associated with the metastatic process and suggest that therapeutic modulation of the protein function may represent a novel approach for inhibiting the metastatic spread of cancer cells.
authors.affiliation: Department of Tumor Biology, the Norwegian Radium Hospital, Oslo, Norway.
authors.forename: G M
authors.initials: GM
authors.lastname: Maelandsmo
authors.forename: E
authors.initials: E
authors.lastname: Hovig
authors.forename: M
authors.initials: M
authors.lastname: Skrede
authors.forename: O
authors.initials: O
authors.lastname: Engebraaten
authors.forename: V A
authors.initials: VA
authors.lastname: Flørenes
authors.forename: O
authors.initials: O
authors.lastname: Myklebost
authors.forename: M
authors.initials: M
authors.lastname: Grigorian
authors.forename: E
authors.initials: E
authors.lastname: Lukanidin
authors.forename: K J
authors.initials: KJ
authors.lastname: Scanlon
authors.forename: O
authors.initials: O
authors.lastname: Fodstad
mesh_terms: D000818:Animals; D001483:Base Sequence; D001859:Bone Neoplasms / Q000235:genetics / Q000473:pathology*; D002135:Calcium-Binding Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D009368:Neoplasm Transplantation; D012516:Osteosarcoma / Q000235:genetics / Q000473:pathology*; D010641:Phenotype; D016337:RNA, Catalytic / Q000494:pharmacology* / Q000627:therapeutic use; D012333:RNA, Messenger / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D051381:Rats; D011923:Rats, Nude; D000071999:S100 Calcium-Binding Protein A4; D009418:S100 Proteins; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D002135:Calcium-Binding Proteins; D009363:Neoplasm Proteins; D016337:RNA, Catalytic; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D000071999:S100 Calcium-Binding Protein A4; D009418:S100 Proteins; C499412:S100a4 protein, rat; C077591:S100A4 protein, human